Article
Efficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim-Chester Disease Harboring Concurrent BRAFV600E and KRASG12R Mutations: A Case Report.
Cancer reports (Hoboken, N.J.) - 1 Dec 2024
Hibino Yuto, Sakai Rika, Takahashi Hiroyuki, Takeda Takaaki, Hirose Natsuki, Tokunaga Mayumi, Washimi Kota, Yokose Tomoyuki, Kasajima Rika, Hiroshima Yukihiko, Miyagi Yohei, Nakajima Hideaki
Abstract excerpt
BACKGROUND: Erdheim-Chester disease (ECD) is a rare form of non-Langerhans cell histiocytosis with diverse clinical manifestations, often associated with mutations in the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway. BRAF and KRAS mutations, which are driver mutations of oncogenes, participate in the same signaling pathway (MAPK/ERK pathway) and are usually mutually...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.